Takeda touts positive first-line leukemia results — but isn't quite ready to reveal...

[cafead]

via Five years after shelling out more than $5 billion for Ariad Pharmaceuticals and its rare leukemia drug Iclusig, Takeda is setting plans in motion for a potential label expansion into the first-line setting — but for now, the pharma giant is keeping its cards close.

article source